摘要肠球菌属是医院感染的条件致病菌.近年来,随着抗菌药物的广泛使用,肠球菌对抗菌药物的耐药率呈逐年上升趋势,甚至出现了耐万古霉素肠球菌(VRE).利奈唑胺是人工合成的恶唑烷酮类抗菌药物,由于不易与其他抑制细菌蛋白合成的抗菌药物发生交叉耐药,曾被认为是治疗VRE的最后一道防线.但自利奈唑胺上市以来,有关耐利奈唑胺肠球菌的报道相继出现.本文就近年来有关肠球菌对利奈唑胺的耐药机制作一综述,以期为耐药监测和新型抗菌药物的研发提供依据.

abstractsEnterococcus is an opportunistic pathogen of nosocomial infection.In recent years, the resistance rate of Enterococcus to antimicrobial agents is increasing with the widespread use of antibiotics, even leading to the development of vancomycin-resistant Enterococcus(VRE).Linezolid is a synthetic oxazolidinone antibiotic, which less likely to generates the cross-resistance with other antimicrobial agents that inhibit bacterial protein synthesis,so it has been regarded as the last line of defense for VRE.However, since the linezolid has appeared on the market, the reports of linezolid-resistant Enterococcus have also emerged.This article reviews the resistance mechanisms of Enterococcus to linezolid in order to provide reference for resistance surveillance as well as the research and development of new antimicrobial agents.